Table 2. Additional power of the qPCR score on different prognostic subgroups.
| Treatment-free survival | Overall survival | ||||||||||||||||||
| qPCR score median TFS | Univariate Cox regression | qPCR score median OS | Univariate Cox regression | ||||||||||||||||
| n | 0/3 | n | 1–2/3 | n | 3/3 | n | HR | 95% Cl | P | 0/3 | n | 1–2/3 | n | 3/3 | n | HR | 95% Cl | P | |
| Binet Stage | 170 | ||||||||||||||||||
| Stage A | ## | >210 | 54 | 88.1 | 52 | 37.0 | 18 | 8.24 | 3.39–20.00 | P<0.0001 | >330 | 54 | >330 | 52 | >330 | 18 | 7.41 | 1.05–52.21 | 0.0443 |
| Stage B-C | 46 | 85.0 | 2 | 26.6 | 28 | 15.5 | 16 | 4.98 | 1.48–16.73 | 0.0095 | >330 | 2 | 241.9 | 28 | 100.5 | 16 | 11.17 | 1.33–94.08 | 0.0265 |
| Mutational status a | 131 | ||||||||||||||||||
| IgVH - Unmutated | 60 | >210 | 2 | 29.0 | 30 | 22.3 | 28 | 3.83 | 1.23–11.95 | 0.0205 | >330 | 2 | 183.0 | 30 | 100.5 | 28 | 7.71 | 0.81–73.25 | 0.7529 |
| IgVH - Mutated | 71 | >210 | 38 | 101.0 | 32 | >210 | 1 | 7.39 | 1.41–38.84 | 0.0181 | >330 | 38 | >330 | 32 | >330 | 1 | 9.59 | 0.12–767.95 | 0.3122 |
| ZAP-70 b | 170 | ||||||||||||||||||
| >134.9 (positive) | 81 | - | 0 | 29.0 | 47 | 24.0 | 34 | 3.03 | 1.03–8.88 | 0.0430 | - | 0 | 183.0 | 47 | 137.2 | 34 | 4.20 | 0.60–29.19 | 0.1466 |
| <134.9 (negative) | 89 | >210 | 56 | 129.5 | 33 | - | 0 | 6.03 | 1.25–29.08 | 0.0251 | >330 | 56 | >330 | 33 | - | 0 | 8.72 | 0.09–806.91 | 0.3486 |
| LPL b | 170 | ||||||||||||||||||
| >15.12 (positive) | 65 | - | 0 | 42.2 | 31 | 24.0 | 34 | 5.34 | 1.54–18.51 | 0.0083 | - | 0 | >330 | 31 | 137.2 | 34 | 15.66 | 2.32–105–91 | 0.0048 |
| <15.12 (negative) | 105 | >210 | 56 | 88.1 | 49 | - | 0 | 14.39 | 3.34–62.09 | 0.0004 | >330 | 56 | 241.8 | 49 | - | 0 | 18.43 | 2.47–137.43 | 0.0045 |
| CLLU1 b | 170 | ||||||||||||||||||
| >14.42 (positive) | 87 | >210 | 22 | 35.5 | 42 | 24.1 | 23 | 7.25 | 3.09–16.97 | P<0.0001 | >330 | 22 | 241.9 | 42 | 152.5 | 23 | 15.66 | 2.32–105.91 | 0.0048 |
| <14.42 (negative) | 83 | >210 | 34 | 126.0 | 38 | 18.7 | 11 | 11.31 | 3.74–34.21 | P<0.0001 | >330 | 34 | >330 | 38 | 82.6 | 11 | 18.43 | 2.47–137.43 | 0.0045 |
| microRNA-29c b | 170 | ||||||||||||||||||
| <4.64 (negative) | 70 | - | 0 | 129.5 | 36 | 24.0 | 34 | 14.51 | 3.75–56.10 | 0.0001 | - | 56 | 241.9 | 44 | 137.2 | 0 | 9.40 | 1.30–67.71 | 0.0261 |
| >4.64 (positive) | 100 | >210 | 56 | 42.2 | 44 | - | 0 | 19.86 | 4.58–86.10 | P<0.0001 | >330 | 0 | >330 | 36 | - | 34 | 15.21 | 0.16–1414.51 | 0.2392 |
| microRNA-223 b | 170 | ||||||||||||||||||
| <138 (negative) | 100 | >210 | 20 | 42.2 | 49 | 24.0 | 31 | 7.93 | 3.18–17.55 | P<0.0001 | >330 | 49 | 241.9 | 31 | 137.2 | 3 | 25.61 | 3.80–172.63 | 0.0009 |
| >138 (positive) | 70 | >210 | 36 | 126.0 | 31 | 114.2 | 3 | 7.47 | 1.50–37.11 | 0.0139 | >330 | 20 | >330 | 36 | 78.4 | 31 | 30.19 | 1.15–794.10 | 0.0411 |
| CD38 b | 161 | ||||||||||||||||||
| >7% (positive) | 74 | >210 | 13 | 35.5 | 39 | 22.3 | 22 | 5.85 | 2.24–15.27 | 0.0003 | >330 | 13 | >330 | 39 | 89.9 | 22 | 11.77 | 1.53–9067 | 0.0180 |
| <7% (negative) | 87 | >210 | 41 | 132.3 | 35 | 21.3 | 11 | 11.18 | 3.86–32.39 | P<0.0001 | >330 | 41 | 241.9 | 35 | 225.1 | 11 | 24.26 | 1.95–302–40 | 0.0132 |
| LDT | 124 | ||||||||||||||||||
| < 1year | 31 | >210 | 1 | 35.5 | 15 | 10.1 | 15 | 12.40 | 2.19–70.33 | 0.0045 | >330 | 1 | >330 | 15 | 82.6 | 15 | 21.31 | 1.64–275.52 | 0.0192 |
| > 1year | 93 | >210 | 45 | 88.5 | 38 | 57.0 | 10 | 6.50 | 2.39–17.64 | 0.0002 | >330 | 45 | 241.9 | 38 | 225.1 | 10 | 7.13 | 0.98–51.66 | 0.0519 |
| Beta-2-microglubulin b | 159 | ||||||||||||||||||
| >2.77 µg (positive) | 73 | >210 | 17 | 36.0 | 45 | 24.0 | 24 | 5.90 | 2.43–14.34 | 0.0001 | >330 | 17 | 241.9 | 45 | 100.5 | 24 | 12.80 | 2.33–70.38 | 0.0034 |
| <2.77 µg (negative) | 86 | >210 | 34 | 88.5 | 30 | 22.3 | 9 | 10.49 | 3.26–33.79 | P<0.0001 | >330 | 34 | >330 | 30 | >330 | 9 | 9.99 | 0.70–142.29 | 0.0894 |
| soluble CD23 b | 153 | ||||||||||||||||||
| >120 U (positive) | 73 | >210 | 7 | 35.5 | 40 | 18.7 | 26 | 5.24 | 2.11–13.03 | 0.0004 | >330 | 7 | 241.9 | 40 | 152.5 | 26 | 6.48 | 1.33–31.65 | 0.0208 |
| <120 U (negative) | 80 | >210 | 42 | 101 | 32 | 24.0 | 6 | 7.36 | 1.61–33.62 | 0.0100 | >330 | 42 | >330 | 32 | 137.2 | 6 | 47.58 | 1.13–2009.23 | 0.0431 |
| Cytogenetic abnormalities c | 115 | ||||||||||||||||||
| del(17p), (11q), (6q), +12, complex | 51 | >210 | 10 | 35.5 | 25 | 24.0 | 16 | 7.53 | 2.19–25.76 | 0.0013 | >330 | 10 | 241.9 | 25 | 89.9 | 16 | 35.05 | 2.76–445.79 | 0.0061 |
| normal,del(13q), other | 64 | >210 | 28 | 87.2 | 30 | 50.0 | 6 | 5.77 | 1.43–23.34 | 0.0140 | >330 | 28 | >330 | 30 | 215.5 | 6 | 8.67 | 0.47–158.47 | 0.4450 |
a
Mutational status is based on a 98% cut-off value.
b
The cut-off determined using ROC curve analysis maximising the concordance with the IgVH status
c
Among patients with unfavorable cytogenetic abnormalities (n = 51), we found 9 patients with a del(17p), 13 with a del(11q), 10 with del(6q), and 18 with a trisomy-12. Furthermore, 1patient presents a complex karyotype associated with poor prognosis. Among patients with favorable cytogenetic abnormalities (n = 64), we found 31 patients with del(13q) and 3 patients with other(s) abnormalities. 30 patients had a normal karyotype.